Trends and disparities in lung cancer and respiratory failure mortality in the US: A 24-year retrospective study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung ...

A meta-analysis of safety and efficacy of datopotamab deruxtecan and sacituzumab govitecan for second line treatment of metastatic non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract ...

Lung cancer is the second most frequent cancer worldwide, and it accounts for 18% of all cancer-related deaths. Most cases of lung cancer involve non-small-cell lung cancer (NSCLC), in which therapy ...

Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, ...

A new editorial was published in Volume 12 of Oncoscience on May 2, 2025, titled "Immune checkpoint inhibitors and myocarditis: Lessons from a nationwide cohort study." In this editorial, Bishal ...

Patients with extensive-stage SCLC who received immunochemotherapy before 15:00 hrs exhibited significantly longer PFS, overall survival. HealthDay News — For patients with extensive-stage small cell ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX) (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) ...

There are many different ways that doctors treat cancer, from chemotherapy to surgery. Another part of cancer treatment that ...

Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis who receive immune checkpoint inhibition for metastatic lung cancer have ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today ...